India wants Serum Institute to lower price of AstraZeneca shot, say sources
Monday, 11 January 2021 () The Indian government has been negotiating with the Serum Institute of India to bring down the price of AstraZeneca's Covid-19 vaccine, delaying the roll-out of the country's immunisation programme. Senior officials have been discussing the terms of the deal with the Serum Institute for weeks, hoping to bring down prices below $3 per shot, one of the sources with direct knowledge told Reuters.
The Government of India announced the launch date of its mass immunisation programme against Covid-19. The vaccinations will begin on January 16, 2021. On January 3, India's drug regulator DCGI had cleared 2 vaccines - Covaxin and Covishield - for emergency use. Covaxin, made by Bharat Biotech, will...
Michael Gove says that the UK’s supply of Covid-19 vaccines for the future has been assured amid threats from the European Union of vaccine export controls on AstraZeneca doses leaving the bloc. Report by Jonesia. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Nepal launched Covid-19 immunisation after India sent vaccines. India sent 10 lakh doses of Covishield vaccines to Nepal as a gift. Nepal PM Oli thanked India and PM Modi for the vaccine consignment. The Serum Institute of India has tied up with AstraZeneca to manufacture Covishield. Thousands of Nepalese frontline workers are set to be vaccinated. Nepal PM said talks are on with India to get more vaccines at a proper price. Oli said, “We got an early chance to administer the Covid-19 vaccine. For this, I thank our neighbouring nation India, its government, the people, and especially Prime Minister Narendra Modi. They sent 10 lakh doses of vaccines to us as a grant within a week of the roll-out in India.” Meanwhile, China is yet to get clearance for its Sinopharm vaccine in Nepal. Nepal has had over 2.7 lakh total covid cases and over 2,000 deaths. Watch the full video for more.
Credit: HT Digital Content Duration: 03:11Published
India once again established its position as a reliable partner in Covid-19 assistance. It dispatched Covishield to Bahrain and Sri Lanka under the Vaccine Maitri Initiative. Sri Lanka to receive a consignment of 50,400 doses, while Bahrain to get 10,800 doses. Covishield developed by Serum Institute of India was loaded to cargo aircraft at Mumbai. The cargo aircraft left Mumbai airport as per schedule at 7:55 am for Manama. The vaccine consignment for Colombo, which delayed for 15 minutes, left at 9:00 am. Meanwhile, India has supplied vaccines to its neighbours under neighbourhood first policy. Bhutan, Maldives, Nepal, Myanmar, Sri Lanka, Afghanistan, Bangladesh received vaccines. India sees international cooperation in the area of fight against Covid-19 as its duty. New Delhi has played the role of the first responder in the region.
Credit: HT Digital Content Duration: 01:29Published
Serum Institute of India's vaccine consignment arrived at Mumbai's Chhatrapati Shivaji Maharaj International Airport on January 28. The consignment containing COVID-19 vaccine will be dispatched to Bahrain and Colombo today. India is helping other countries with the import of COVID vaccine amid the pandemic.
Prime Minister Narendra Modi said India will soon make available many more covid-19 vaccines to other countries. He also highlighted India's success in the fight against Covid-19. PM Modi said that he wants to assured global business community that the situation will now change rapidly. “Many more India-made vaccines will soon be made available to the world. India's upcoming vaccines will help other countries to fight pandemic at swifter pace. I want to assure global business community that situation will now change rapidly,” he said. The prime minister was addressing the World Economic Forum's online Davos agenda summit.
Credit: HT Digital Content Duration: 03:51Published
Prime Minister Boris Johnson visits the Lighthouse Laboratory at the Queen Elizabeth University Hospital campus in Glasgow, where coronavirus tests are processed. Report by Jonesia. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Serum Institute of India (SII) CEO Adar Poonawalla on January 22 informed that there is no impact of fire on the production of 'Covishield' vaccine. "The extent of the damage is more than 1,000 crores...
The expert panel is likely to approve the vaccine developed by AstraZeneca and Oxford University for emergency use on Friday, Reuters reported quoting sources.... IndiaTimes Also reported by •Mid-Day •Hindu